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Influenza A virus (IAV) is a human respiratory pathogen that causes seasonal epidemics
and occasional global pandemics with devastating levels of morbidity and mortality.
Currently approved treatments against influenza are losing effectiveness, as new viral
strains are often refractory to conventional treatments. Thus, there is an urgent need to
find new therapeutic targets with which to develop novel antiviral drugs. The common
strategy to discover new drug targets and antivirals is high throughput screening.
However, most current screenings for IAV rely on the engineered virus carrying a reporter,
which prevents the application to newly emerging wild type flu viruses, such as 2009
pandemic H1N1 flu. Here we developed a simple and sensitive screening assay for
wild type IAV by quantitatively analyzing viral protein levels using a Dot Blot Assay in
combination with the LI-COR Imaging System (DBALIS). We first validated DBALIS in
overexpression and RNAi assays, which are suitable methods for screening host factors
regulating viral infection. More importantly, we also validated and initiated drug screening
using DBALIS. A pilot compound screening identified a small molecule that inhibited
IAV infection. Taken together, our method represents a reliable and convenient high
throughput assay for screening novel host factors and antiviral compounds.
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INTRODUCTION
Influenza A virus is a highly transmissible respiratory pathogen and presents a continued threat
to global health with considerable economic and social impact (Kawaoka, 2006; Hale et al., 2010;
Fukuyama and Kawaoka, 2011; Tscherne and Garcia-Sastre, 2011). In spite of vaccines and antiviral
drugs flu remains a major burden to human health in the US and worldwide. In times of flu
pandemics these numbers can significantly rise and the threat to the health care system itself is a
serious concern (Schultz-Cherry and Jones, 2010; Medina and Garcia-Sastre, 2011; Govorkova and
McCullers, 2013). There are two types of drugs used to treat flu infection. The amantidines block
entry of virions through the acidified endosomal compartment. The other anti-flu treatments are
sialic acid mimics, which inhibit the activity of viral neuraminidase and prevent release of new viral
particles. Both types of anti-influenza therapies directly target the activity of viral genes. However,
there has been a rapid worldwide increase in resistance to these drugs among circulating flu viruses
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(Medina and Garcia-Sastre, 2011; Govorkova and McCullers,
2013; Kamali and Holodniy, 2013; Samson et al., 2013). Thus, it
is pressing to develop new antiviral strategies.
IAV is a member of the Orthomyxoviridae family and
possesses eight segments of negative-sense single-stranded RNA
genome that encode 11 major viral proteins. IAV initiates
infection by hemagglutinin (HA) binding sialic acid sugars on
plasma membrane. Then viral particle are ferried into the late
endosome by endocytosis. The acidic environment in the late
endosome induces a conformational change of HA to mediate
membrane fusion. The matrix 2 ion channel protein acidifies
the core of the virus, which causes to the release of viral
ribonucleoprotein complexes (vRNPs) from matrix 1 proteins
into cytoplasm. vRNPs consist of nucleoprotein (NP) and
heterotrimeric viral polymerase subunit proteins [polymerase
acid (PA), polymerase basic 1 and 2 (PB1 and PB2)]. The vRNPs
are transported into nucleus, where the RNA-dependent RNA
polymerase begins replication and transcription. Viral RNA is
exported into the cytoplasm and translated. After new viral
particles are assembled, the mature virus buds off from the
cell once its neuraminidase has cleaved sialic acid residues
from the host cell. Briefly, the influenza virus life cycle can
be divided into three distinct stages (entry, replication, and
egress), each of which could be targeted by small molecule
inhibitors.
Recently, three types of high throughput reporter assays
have been developed for indirect measurement of IAV infection
(Beyleveld et al., 2013). The first type of assay is based on IAV
minigenome system. Cells are transfected with a plasmid that will
generate a virus-like RNA, which encodes a reporter gene under
control of the viral polymerase regulatory sequences (Su et al.,
2010; Ozawa et al., 2013; Wang et al., 2015). The second way is
to generate an IAV virion in which one viral gene is replaced by
a reporter gene. The engineered virus is replication-incompetent.
For example, König et al. generated a recombinant influenza virus
where the open reading frame (ORF) of HA was replaced with
Renilla luciferase (König et al., 2010). The virus needs to grow
in a cell-line that stably expresses HA to complement the loss of
the viral segment encoding HA. The third type is to generate a
replication competent reporter IAV (Manicassamy et al., 2010;
Heaton et al., 2013; Pan et al., 2013; Karlsson et al., 2015). One
of examples is the PR8 IAV carrying a Gaussia luciferase (GLuc)
on its PB2 segment. The GLuc ORF was inserted after the PB2
ORF, which contained a mutated packaging signal on its 3′ end.
A functional PB2 packaging signal was then repeated on the 3′
end of the GLuc ORF (Heaton et al., 2013). However, all these
assays require expression of a reporter gene as an indicator of
viral polymerase activity. The feasibility and variability of this
requirement limits its application to wild type IAVs, such as
emerging new viral strains. Thus, there is a need for developing a
general non-reporter based screening assay.
Here, we report a novel assay suitable for high throughput
screening inhibitors targeting IAV infection. Our assay directly
measures wild type virus infection activity by quantitatively
analyzing viral protein levels using DBALIS. We validated the
assay in overexpression and RNAi experiments. Furthermore,
we initiated a pilot compound screening and identified a
small molecule that inhibits IAV infection. Hence, our data
demonstrate that DBALIS is suitable for high throughput
screening of novel host restriction factors and anti-influenza
drugs.
MATERIALS AND METHODS
Cells and Viruses
HEK293 cells (ATCC, #CRL-1573) were maintained in
Dulbecco’s minimal essential medium (Life Technologies,
#11995-065) containing antibiotics (Life Technologies, #15140-
122) and 10% Fetal Bovine Serum (Life Technologies,
#26140-079). A549 cells (ATCC, #CCL-185) were cultured
in RPMI Medium 1640 (Life Technologies, #11875-093) plus
10% fetal bovine serum and 1X MEM Non-Essential Amino
Acids Solution (Life Technologies, # 11140-050).
Influenza A/Puerto Rico/8/34 (PR8) was purchased from
Charles River Laboratories (#10100374). Influenza A/WSN/33
(WSN/33) and PR8 IAV carrying a Gluc gene (PR8-Gluc; Heaton
et al., 2013) were generous gifts from Dr. Peter Palese (Mount
Sinai School of Medicine, NY, NY). IAVs was propagated in
specific pathogen-free fertilized eggs Premium Plus (Charles
River Laboratories, Wilmington, MA) according to previously
published protocols (Szretter et al., 2006).
Plaque Assay
IAV was tittered by plaque assay as described by Matrosovich
et al. (2006). Briefly, 1.2 × 106 MDCK cells/ml were split into
six-well-plates. After 2X washes with DMEM, serial dilutions of
flu virus were adsorbed onto the cells for 1 h. Cells were covered
with DMEM containing 2×Avicel RC591 NF (FMCBiopolymer,
Philadelphia, PA) and 1 µg/ml TPCK-trypsin (Thermo Fisher
Scientific, #20233). Crystal violet staining was performed 48
h.p.i., and visible plaques were counted.
Dot Blot Assay Using LI-COR Imaging
System
The flowchart of this assay is depicted in Figure 1. Cells were
seeded into a 96-well-plate. After transfection or treatment, cells
were infected with influenza virus. After 16 h, about 2× 104 cells
in the well were lysed in 25 µl TAP lysis buffer [50 mM Tris-
HCl (pH 7.5), 10 mM MgCl2, 100 mM NaCl, 0.5% Nonidet P40,
10% glycerol, Complete EDTA-free protease inhibitor cocktail
tablets (Roche, #11873580001)] for 30 min at 4◦C. Then the
plate was centrifuged for 30 min at 2000 g. Two-microliter lysate
from each well was transferred onto a nitrocellulose membrane
using a multichannel pipettor. After air-drying for 30 min at
room temperature, the dot blot membrane was blocked with
Odyssey Blocking Buffer (LI-COR Biosciences, # 927-40000) for
1 h. Then the blot was washed with 1X TBS buffer for 30 min and
incubated with anti-β-actin (Abcam, #ab8227, 1:1000 dilution)
and anti-NP (BEI resources, # NR-4282, 1:1000 dilution) at 4◦C
for 16 h. Then the blot was 3X washed with 1X TBS (each
time for 10 min) and incubated with secondary antibodies, goat
anti-rabbit IRDye@680 (1:10000 dilution) and goat anti-mouse
IRDye@800 (1:10000 dilution) at room temperature for 1 h.
After washing 3X with 1X TBS (each time for 10 min), the
Frontiers in Microbiology | www.frontiersin.org 2 June 2016 | Volume 7 | Article 858
Wang et al. A Novel Screening Method for Influenza A Virus
FIGURE 1 | Flowchart of DBALIS. The procedures are detailed in the Materials and Methods.
dot blot membrane was placed on the reading glass platform
of the LI-COR Odyssey R© Infrared Imaging System (LI-COR
Biotechnology, NE) with the reader is set for a 96-well-plate
reading. The blot was scanned using the 800 nm channel for viral
NP detection and the 700 nm wavelength for anti-β-actin, which
is the control for cell numbers. Blank negative control dots were
set using the LI-COR Odyssey software. Each dot was quantified
using LI-COR Odyssey software, ImageStudioTM according to
the manufacturer’s instructions.
Real-Time PCR
Total RNA was prepared using RNeasy columns (Qiagen, #
74136). One microgram RNA was transcribed into cDNA
using QuantiTect reverse transcription kit (Qiagen, # 205311).
Twenty microliter SYBR Green PCR reaction mix (Roche
Applied Science), containing 1/10 of the synthesized cDNA plus
an appropriate oligonucleotide primer pair, were run on the
LightCycler 480 (Roche). The comparative Ct method was used
to determine relative mRNA expression of genes as normalized
by the housekeeping gene, GAPDH. The primer sequences
are: TRIM32: sense, 5′-CCGGGAAGTGCTAGAATGCC-3′,
antisense, 5′-CAGCGGACACCATTGATGCT-3′; FKBP8: sense,
5′-GGAGTACAGTGAGGCCATCC-3′, antisense, 5′-GGA
TCGTCTTGTTGGAAGGT-3′; GAPDH, sense, 5′-AGGTGA
AGGTCGGAGTCA-3′, antisense, 5′-GGTCATTGATGGCAA
CAA-3′.
Plasmid Transfection and RNA Interference
(RNAi)
Control vector or eight plasmids were transfected individually
into HEK293 cells using Lipofectamine 2000 Transfection
Reagent (Life Technologies, # 11668-019) according to the
manufacturer’s protocol. After 24 h, cells were infected
with IAV. These genes were used for this study: TRIM32
(BC003154), STUB1 (BC0075456), IQSEC (BC010267),
GALK1 (BC 001166), PDCD6 (BC050597), HAUS6
(NM 001270890.1), FKBP8 (NM_012181.3), and HAX1
(BC005240.1).
The control RNAi used was Dharmacon siGENOME
Non-Targeting Control siRNA #2 (# Dharmacon D-001210-
02). A549 cells were transfected with siRNA duplexes
using Lipofectamine RNAiMAX Transfection Reagent (Life
Technologies, # 13778030) according to manufacturer’s protocol.
Knockdown was allowed to proceed for 72 h before cells were
infected with IAV. RNAi target sequences used: TRIM32:
sense, 5′-GACCGTGGTAACTATCGTATA-3′; FKBP8: sense,
5′-GGAAGAGGATGACCTGAGTGA-3′.
Reporter Assay
Cells were aliquoted in 96-well-plates for 24 h prior to IAV
infection. Cells were infected with PR8-GLuc. After 1 h the
viral inoculum was aspirated, cells were washed twice and
incubated at 37◦C with 0.2% BSA-DMEM without serum. Cells
were lysed 16 h post of infection and the luciferase assay was
performed using BioLux Gaussia Luciferase Assay Kit (NEB,
Ipswich, MA).
Cell Viability
Cell viability was assessed by using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega) according to
the manufacturer’s instructions. Briefly, 2 µl lysate was
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added into 20 µl CellTiter-Glo reagent preloaded in a 96-
well-plates. Then the plate was subjected to luminescence
measurement.
Statistical Analysis
Z′ factor is a dimensionless calculation used to assess the quality
of a population of sample compounds tested (Zhang et al., 1999).
The Z′ value was calculated as follows: Z′ = 1 – 3 × (SD of
positive control + SD of negative control)/|mean of positive
control − mean of negative control|, where SD represents the
standard deviation. Z′ value between 0.5 and 1.0 is considered
as an excellent assay for high throughput screening.
RESULTS
Establishment of DBALIS
We first examined the feasibility of DBALIS on IAV infection.
To compare DBALIS and reporter-based assay in parallel, we
used influenza PR8-GLuc virus. Lung epithelial A549 cells
in 96-well-plates were infected with 0.001, 0.01, or 0.1 MOI
of IAV PR8-Gluc for 16 h. Two microliter of cell lysates
were applied onto nitrocellulose membrane for the Dot Blot.
Viral NP and host β-actin protein levels have been used to
indicate viral infection activity and cell number, respectively.
The dot membrane was incubated with anti-NP and anti-β-
actin antibodies for 16 h in a shaker at 4◦C. The intensities
of NP in each dot were analyzed by ImageStudioTM. Using
the same cell lysates, luciferase activity was also determined by
reporter assay. As shown in Figure 2A, both assays demonstrate
that the reporter activity and the protein levels of NP were
increased roughly by a factor of 10, which is highly correlated
to the titers of IAV. The protein levels of β-actin had minimal
changes (Figure 2B), indicating comparable cell numbers in
these samples. Therefore, DBALIS exhibited similar sensitivity,
robustness, and correlation as the reporter assay that had
previously been established for high throughput screens. Taken
together, we present a novel assay for quantitative measurement
of IAV infection.
Functional Validation of DBALIS in
Overexpression and RNA Interference
Assays
We next explored the application of DBALIS on gain- and loss-
of function screenings of host factors targeting IAV. We first
selected eight host factors that have been shown to interact with
influenza PB1 protein previously in our lab (Fu et al., 2015).
We overexpressed each candidate gene or a control vector in
HEK293 cells. After 24 h cells were infected with 0.1 MOI of
PR8 IAV for 16 h. The ratio of NP to β-actin was calculated.
The relative viral infection activity was determined by comparing
to the NP/actin ratio of control vector. The NP/actin ratio
of vector was set at one. DBALIS found that overexpression
of TRIM32, STUB1 and FKBP8 reduced influenza infection
activity from two to four fold (Figure 3A), indicating their
role in viral restriction. We also performed RNA interference
(RNAi) targeting the above eight host factors. Scrambled control
siRNA or siRNA duplex of each gene was transfected into A549
cells for 72 h. Then cells were infected with 0.1 MOI of PR8
IAV for 16 h. DBALIS showed that knockdown of TRIM32
increased NP protein level by a 2.9-fold over control RNAi
(Figure 3B). RNAi depletion of STUB1 and FKBP8 also increased
viral NP level by 2.1 and 2.3-fold, respectively. Knockdown
efficiency of these three genes was about 70 to 85% (Figure 3C).
CellTiter Glo R© assays showed that RNAi had marginal effects
on cell viability (Figure 3C). TRIM32 and STUB1 are genes
known to limit influenza infection (Fu et al., 2015). Thus,
the confirmation of known anti-influenza genes validates the
reliability of DBALIS. Taken together, these data prove the
concept of DBALIS in the successful application of the technique
to high throughput screening of host factors regulating IAV
infection.
Functional Validation of DBALIS in an
Anti-Influenza Drug Assay
To establish the application of DBALIS for screening inhibitors
targeting IAV infection, we used DBALIS to examine the
FIGURE 2 | Comparison of DBALIS with viral reporter assay. (A) Lung epithelial A549 cells in 96-well-plates were infected with 0.001, 0.01, or 0.1 MOI of IAV
PR8-Gluc for 16 h. Two microliter of the same cell lysates were used for DBALIS and reporter assays, respectively. (B) DBALIS determined the Intensity of β-actin in
the same samples used in (A) All experiments were repeated three times and error bars are indicated.
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FIGURE 3 | Applying DBALIS to gain- and loss- of function screenings. (A) HEK293 cells were transfected with control vector or the indicated genes for 24 h.
Cells were infected with 0.1 MOI IAV PR8 for 16 h. The ratio of NP to β-actin was calculated. The relative viral infection activity was determined by comparing the
NP/actin ratio to the control vector that was set as one. All experiments were repeated three times and two-tailed student t-test was performed. An asterisk indicates
P < 0.05. (B) A549 cells were transfected with scrambled control siRNA and indicated siRNA oligos. After 72 h, cells were infected with 0.1 MOI IAV PR8 for 16 h.
The relative IAV infection activities were determined by DBALIS. All experiments were repeated three times and two-tailed student t-test was performed. An asterisk
indicates P < 0.05. (C) Knockdown efficiency and cell viability were determined by real-time PCR and CellTiter-Glo®, respectively. A549 cells were transfected with
scrambled control siRNA or the indicated siRNA oligos. After 72 h, mRNA levels and cell viability were examined. All experiments were repeated three times.
FIGURE 4 | Validation of DBALIS in drug screenings. (A) A549 cells were incubated with 50 µM amantadine hydrochloride and 25 nM bafilomycin A1 for 4 h,
then infected with PR8 IAV for 16 h. Viral infection activity and cell viability were determined by DBALIS and CellTiter Glo®, repectively. (B) Determination of R2-value.
A549 cells were treated with various concentration of Amantadine for 72 h. IAV infection activity was then determined by DBALIS. R2 was calculated in two
independent experiments (each experiment was in triplicates). The triangle stands for the data point of IAV reporter activity.
effects of two known anti-influenza drugs, amantadine and
bafilomycin A1. Amantadine is a known inhibitor of IAV
M2 ion channel (Wang et al., 1993). Bafilomycin A1 is an
endosomal acidification inhibitor that has been shown to block
viral endocytic entry (Ochiai et al., 1995). A549 cells were
incubated with 50 µM amantadine hydrochloride or 25 nM
bafilomycin A1 for 4 h, then infected with PR8 IAV. DBALIS
showed both drugs inhibited IAV infection with minimal effects
on cell viability (Figure 4A). To determine the robustness of
the assay, we examined the correlation of reproducibility of the
assay using serial dilutions of bafilomycin A1. The high R2-
value (r2 = 0.98, P < 0.003) indicates the high reproducibility
of the assay (Figure 4B), validating the DBALIS in drug
screening.
Pilot Screening Identifies UCN-01 as a
Novel Influenza Inhibitor
We initiated a pilot screen of 50 small molecules targeting
various signaling pathways. A549 cells were seeded into a 96-
well-plate. In the plate, 10 wells were treated with negative
and positive controls, DMSO, and Amantadine, respectively.
After treatment with inhibitors for 4 h, cells were infected
influenza A/WSN/33 (WSN/33). After screening using DBALIS
(Figure 5A), we utilized the Z′ factor to evaluate the quality of
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FIGURE 5 | Drug screening identified UCN-01 as a novel inhibitor of influenza A virus. (A) A549 cells were treated with DMSO, Amantadine, or 50 small
molecules for 4 h Then cells were infected WSN/33 IAV for 16 h. Relative infection activity was determined by DBALIS. Blue circles represent negative controls of
DMSO while red circles are the positive controls of Amantadine. The arrow indicates UCN-01. (B) Chemical structure of UCN-01. (C) A549 cells pretreated with
designated concentrations of UCN-01 were infected with 0.001 MOI of WSN/33 IAV. Culture supernatants containing IAV were titered on MDCK cells and plaques
were enumerated.
the method in high throughput assays. The Z′ factor is reported
to reflect both the assay signal dynamic range and the data
variation associated with the signal measurements (Zhang et al.,
1999). The mean and standard deviation of positive and negative
controls were 0.25, 0.032, 1.051, 0.036, respectively. The Z′ factor
of our drug screening was 0.745, a score that is considered
robust and reliable, suggesting that DBALIS is suitable for high
throughput screening for small molecules restricting influenza
infection.
A small molecule, UCN-01 exhibited a significant inhibitory
effect on NP expression while none of the compounds in the
screening exhibited cytotoxicity in A549 cells (Figure 5A). UCN-
01 is 7-hydroxystaurosporine, which inhibits the enzymatic
activity of protein kinase C (PKC; Figure 5B) (Takahashi et al.,
1987). Primary screening suggests that UCN-01 possesses anti-
influenza virus activity. Therefore, we further assessed the
inhibitory effect of UCN-01 by plaque assays of WSN/33 IAV.
Plaque assays showed that 1 µM UCN-01 inhibited viral growth
by more than 100-fold (Figure 5C). These results substantiate
that UCN-01 is a bona fide inhibitor of IAV.
DISCUSSION
To date, most published works use reporter systems to screen
host factors and inhibitors. However, the reporter system reflects
viral infection indirectly and luciferase activity could be affected
by several factors, such as buffer and temperature (Kricka and
Deluca, 1982; Harrison et al., 2006). Moreover, the availability
of existing reporter systems or the feasibility of constructing
new ones interferes with the application to wild type and newly
emerging IAVs. Here we develop a new assay combining Dot
Blot and the LI-COR imaging system that is suitable for sensitive
and quantitative high throughput screening. DBALIS is an easy
and simple assay that only needs an antibody against a viral
protein and the LI-COR Imaging System. Thus, DBALIS provides
an advantage as it allows screening of wild type IAVs, which
is potentially applicable for measurement of the infections with
various types and strains of viruses. We demonstrate that this
assay can be applied to gene function and small molecule
screenings. We also successfully validate the use of DBALIS to
examine viral infection with two wild type IAV strains (PR8
and WSN/33) in two human cell lines (HEK293 and A549).
These data suggest the versatility and broad application of
DBALIS.
Although DBALIS is an efficient high throughput screening
method, there are several limitations. First, it requires high
quality antibodies for Dot Blot. Secondly, proteins are not
separated in Dot Blot, so low steric size proteins could be
masked by high steric size proteins on the spot surface. Thirdly,
in comparison with reporter virus-based screening, DBALIS
is relative laborious and time consuming. Last, DBALIS uses
β-actin as an input control. At higher total protein loads as
required for the detection of low-abundance proteins, β-actin-
specific antibodies are not reliable to distinguish differences
in actin protein levels (Dittmer and Dittmer, 2006). Despite
of these limitations, the DBALIS provides an alternative and
complementary method for reporter-based screening.
Our pilot drug screening identified UCN-01 as an IAV
inhibitor. UCN-01 was originally isolated from the culture
broth of Streptomyces species as a PKC selective inhibitor
(Takahashi et al., 1987). PKC has been implicated in viral entry
processes. The entry of several enveloped viruses, including
influenza viruses, poxviruses, and Herpesviruses, has been
proposed to require PKC (Constantinescu et al., 1991). During
entry, influenza virus traverses the endocytic pathway and has
the ability to activate PKC upon binding to host cell surface
receptors (Kunzelmann et al., 2000). Another PKC inhibitor,
bisindolymaleimide I, also restricts IAV infection (Root et al.,
2000), attesting to the potential of UCN-01 as an anti-influenza
agent.
UCN-01 also shows antitumor activity, however, the precise
mechanism is still not fully understood. Clinical studies show that
UCN-01 causes arrest of cell cycle progression at G1/S phase at
concentrations that reduce PKC activity (Akiyama et al., 1999;
Abe et al., 2001). In addition, UCN-01 also induces apoptosis
and sensitization to DNA-damaging agents (Fuse et al., 2005).
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Several phase I and II studies of UCN-01 either as monotherapy
or in combination with cytotoxic agents have been reported
(Fuse et al., 2005; Li et al., 2012; Ma et al., 2013). Whether the
antitumor activity of UCN-01 affects IAV infection will need
further investigation.
In summary, we established and validated a simple,
convenient, and reliable high throughput-screening assay
to monitor IAV infection. Using this system, we identified a
promising candidate inhibitor of IAV. This novel screen assay
will advance the discovery of novel antivirals and identification
of new host factors controlling viral infection.
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